Get Regeneron Pharmaceuticals alerts:Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) – Analysts at Leerink Partnrs boosted their Q3 2025 earnings per share (EPS) estimates for Regeneron Pharmaceuticals in a report issued on Tuesday, September 30th. The consensus estimate for Regeneron Pharmaceuticals’ current full-year earnings is $35.92 per share. Leerink Partnrs also issued estimates for Regeneron Pharmaceuticals’ FY2025 earnings at $31.96 EPS. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. Recommended StoriesReceive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.